For his thesis, Derek Christie studied people who walk outdoors for more than one hour per day. Little research has been done into these frequent walkers, who could nevertheless help to shape public policies on mobility.

Analyses of the EXPAND study showed that siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis